Clinical trials: Older People
COVID-19
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older.
- Trial name
- NCT04869592
- Testing
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Where
- China
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older .
- Trial name
- NCT06678607
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, PPSV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Pertussis, Tetanus
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have received their primary series of DTaP…
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00457249
- Testing
- ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
- Where
- 19 sites in United States
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
People Aged 55-70 Years
The Effect of Probiotics on the Improvement of Digestive Function and Well-being in the Elderly
To evaluate the effectiveness and safety of the use of probiotics as food supplements compared to placebo in improving digestive function and well-being in older adults.
- Trial name
- NCT06648590
- Testing
- Probiotic
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Hiv, Loneliness
ADHOC Mindfulness-Based Research
The AMBR Study (ADHOC Mindfulness-Based Research Study) is a randomized controlled trial that examines the effectiveness of teaching mindfulness-based techniques through online lessons to combat loneliness, anxiety, and…
- Conditions
- Hiv, Loneliness, Depression, Anxiety
- Trial name
- AMBR (NCT04580082)
- Testing
- Mindfulness lessons
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Mazonson & Santas Inc.
Pertussis (Whooping Cough), Diphtheria
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07894055
- Testing
- Tdap vaccine
- Where
- China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
COVID-19
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
Subjects aged 18 and above who have been completed primary or booster vaccination of COVID-19 inactivated vaccines for 3 months or more, to conduct a randomized, parallel controlled, double-blind, single-center phase I clinical…
- Trial name
- NCT05765604
- Testing
- Recombinant COVID-19 variant vaccine(Sf9 cell), Recombinant COVID-19 vaccine(CHO cell)
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Diphtheria, Tetanus
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td
To compare the seroprotection rates and booster responses to Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the seroprotection rates and booster responses to the US-manufactured Tetanus and Diphtheria…
- Trial name
- NCT00601835
- Testing
- Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
- Where
- 2 sites in United States
- Volunteers
- 3,651 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza…
- Trial name
- NCT01884519
- Testing
- Fluarix/Influsplit SSW® (2013-2014 season)
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and…
- Trial name
- NCT04566770
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Clostridoides Difficile Associated Disease
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older.
- Trial name
- BEETHOVEN (NCT07282665)
- Testing
- C.difficile vaccine
- Where
- 185 sites in United States, Argentina and 2 more
- Volunteers
- 32,500 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2
Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over
This is a single-center, randomized, blinded, placebo-controlled clinical trial to evaluate the protective efficacy, safety and immunogenicity of one dose of the SARS-CoV-2 variant (Omicron BA.5) mRNA vaccine in people aged 18…
- Trial name
- NCT05745545
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution
- Where
- China
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Pneumococcal Infectious Disease
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.
- Trial name
- NCT06678620
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3
- Where
- 2 sites in China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
COVID-19
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at…
- Trial name
- NCT07861542
- Testing
- Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M
- Where
- 20 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pneumococcal Vaccines
Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine
The purpose of this experiment is to evaluate the safety and immunogenicity of the 26 valent pneumococcal conjugate vaccine in the population aged 2 months and above.
- Trial name
- NCT06703203
- Testing
- 26-Valent pneumococcal conjugate vaccine, 23-Valent pneumococcal polysaccharide vaccine, 13-Valent pneumococcal conjugate vaccine
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pertussis (Whooping Cough), Diphtheria
A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the safety and tolerability of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07492303
- Testing
- Tdap vaccine
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
SARS-CoV-2
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled.
- Trial name
- NCT05939648
- Testing
- SARS-CoV-2 Bivalent mRNA Vaccine, Saline
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Coronavirus
Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Popular title: Clinical study of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells). Purpose of the study: Main objectives: To evaluate the immunogenicity and safety of Omicron BA.4/5-Delta…
- Trial name
- NCT05850507
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older…
- Trial name
- NCT05770180
- Testing
- Recombinant COVID-19 variant vaccine (Sf9 cell), Recombinant COVID-19 vaccine (CHO cell), Recombinant COVID-19 vaccine (Sf9 cell)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.